BAKER BROS. ADVISORS LP - 11 Aug 2026 Form 4 Insider Report for Replimune Group, Inc. (REPL)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: REPL
Reported as of: 11 Aug 2026
Net transaction value: +$32,999,987
SEC form: 4
Accepted by SEC: 11 Aug 2026, 17:46:08 UTC
Prior SEC filing: 16 Jul 2026
Source filing: View source filing
Reporting owner signature: By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing

Key filing fact

BAKER BROS. ADVISORS LP filed Form 4 for Replimune Group, Inc. (REPL) on 11 Aug 2026.

Key facts

This page summarizes BAKER BROS. ADVISORS LP's Form 4 filing for Replimune Group, Inc. (REPL).
2 reported transactions and 12 derivative rows are listed below.
Accepted by SEC: 11 Aug 2026, 17:46.

Change

Previous filing in this sequence was filed on 16 Jul 2026.
Current net transaction value: +$32,999,987.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (6)

CIK 0001263508 Primary reporting owner

BAKER BROS. ADVISORS LP

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Signature date: 11 Aug 2026

CIK 0001580575

Baker Bros. Advisors (GP) LLC

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Signature date: 11 Aug 2026

CIK 0001551139

667, L.P.

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Signature date: 11 Aug 2026

CIK 0001363364

Baker Brothers Life Sciences LP

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker Brothers Life Sciences, L.P., Name: Scott L. Lessing, Title:President /s/
Signature date: 11 Aug 2026

CIK 0001087940

BAKER FELIX

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: /s/ Felix J. Baker
Signature date: 11 Aug 2026

CIK 0001087939

BAKER JULIAN

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: /s/ Julian C. Baker
Signature date: 11 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

REPL transaction Derivative

2026 $0.0001 Prefunded Warrants

Purchase

Transaction value: $1,524,299
Shares: +126,394
Change %
Price: $12.06
Shares after: 126,394
Date: 11 Aug 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 126,394
Exercise price: $0.000100
Footnotes: F1, F2, F3, F4, F5, F6

REPL transaction Derivative

2026 $0.0001 Prefunded Warrants

Purchase

Transaction value: $1,524,299
Shares: +126,394
Change %
Price: $12.06
Shares after: 126,394
Date: 11 Aug 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 126,394
Exercise price: $0.000100
Footnotes: F1, F2, F3, F4, F5, F6

REPL transaction Derivative

2026 $0.0001 Prefunded Warrants

Purchase

Transaction value: $1,524,299
Shares: +126,394
Change %
Price: $12.06
Shares after: 126,394
Date: 11 Aug 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 126,394
Exercise price: $0.000100
Footnotes: F1, F2, F3, F4, F5, F6

REPL transaction Derivative

2026 $0.0001 Prefunded Warrants

Purchase

Transaction value: $1,524,299
Shares: +126,394
Change %
Price: $12.06
Shares after: 126,394
Date: 11 Aug 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 126,394
Exercise price: $0.000100
Footnotes: F1, F2, F3, F4, F5, F6

REPL transaction Derivative

2026 $0.0001 Prefunded Warrants

Purchase

Transaction value: $1,524,299
Shares: +126,394
Change %
Price: $12.06
Shares after: 126,394
Date: 11 Aug 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 126,394
Exercise price: $0.000100
Footnotes: F1, F2, F3, F4, F5, F6

REPL transaction Derivative

2026 $0.0001 Prefunded Warrants

Purchase

Transaction value: $1,524,299
Shares: +126,394
Change %
Price: $12.06
Shares after: 126,394
Date: 11 Aug 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 126,394
Exercise price: $0.000100
Footnotes: F1, F2, F3, F4, F5, F6

REPL transaction Derivative

2026 $0.0001 Prefunded Warrants

Purchase

Transaction value: $31,475,688
Shares: +2,609,946
Change %
Price: $12.06
Shares after: 2,609,946
Date: 11 Aug 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 2,609,946
Exercise price: $0.000100
Footnotes: F1, F2, F3, F5, F6, F7

REPL transaction Derivative

2026 $0.0001 Prefunded Warrants

Purchase

Transaction value: $31,475,688
Shares: +2,609,946
Change %
Price: $12.06
Shares after: 2,609,946
Date: 11 Aug 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 2,609,946
Exercise price: $0.000100
Footnotes: F1, F2, F3, F5, F6, F7

REPL transaction Derivative

2026 $0.0001 Prefunded Warrants

Purchase

Transaction value: $31,475,688
Shares: +2,609,946
Change %
Price: $12.06
Shares after: 2,609,946
Date: 11 Aug 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 2,609,946
Exercise price: $0.000100
Footnotes: F1, F2, F3, F5, F6, F7

REPL transaction Derivative

2026 $0.0001 Prefunded Warrants

Purchase

Transaction value: $31,475,688
Shares: +2,609,946
Change %
Price: $12.06
Shares after: 2,609,946
Date: 11 Aug 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 2,609,946
Exercise price: $0.000100
Footnotes: F1, F2, F3, F5, F6, F7

REPL transaction Derivative

2026 $0.0001 Prefunded Warrants

Purchase

Transaction value: $31,475,688
Shares: +2,609,946
Change %
Price: $12.06
Shares after: 2,609,946
Date: 11 Aug 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 2,609,946
Exercise price: $0.000100
Footnotes: F1, F2, F3, F5, F6, F7

REPL transaction Derivative

2026 $0.0001 Prefunded Warrants

Purchase

Transaction value: $31,475,688
Shares: +2,609,946
Change %
Price: $12.06
Shares after: 2,609,946
Date: 11 Aug 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 2,609,946
Exercise price: $0.000100
Footnotes: F1, F2, F3, F5, F6, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") purchased 126,394 and 2,609,946 warrants to purchase common stock ("Common Stock") of Replimune Group, Inc. (the "Issuer") ("2026 $0.0001 Prefunded Warrants"), respectively, for $12.0599 per warrant pursuant to an underwritten public offering that closed on August 11, 2026.

Footnote F2

The 2026 $0.0001 Prefunded Warrants have no expiration date and are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the "Maximum Percentage") immediately prior to and following such exercise.

Footnote F3

By written notice to the Issuer, the Funds may from time to time increase or decrease the Maximum Percentage applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase or decrease will not be effective until the 61st day after such notice is delivered to the Issuer.

Footnote F4

After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

Footnote F5

Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.

Footnote F6

Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

Footnote F7

After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC remarks

Michael Goller, a full-time employee of Baker Bros. Advisors LP, is a director of Replimune Group, Inc. (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer.